3 Australian Growth Stocks With Revenue Growth Up To 37%

Oil just pushed above US$100 after fresh conflict around key shipping routes, and that affects everything from freight costs to supermarket shelves. Australian high growth opportunities that management and analysts already back can look especially interesting when inflation stories return to the front page. This article walks through three such stocks from a local high growth, high conviction pool so you can decide whether they belong on your watchlist.

The three stocks below are just a sample from this high growth, high conviction idea, and the full screen surfaced 24 more companies with similarly compelling stories that are not covered here.

To identify and analyze the highest conviction opportunities that match your own criteria, head straight into the High Growth High Conviction screener.

Emerald Resources (ASX:EMR)

Emerald Resources is a gold producer focused on the 100% owned Okvau Gold Project in Cambodia, a clear fit with the High Growth High Conviction theme. Mine operations generate about A$602 million of its roughly A$612 million revenue, with other income around A$11 million. The business is valued at about A$4.4b.

Emerald Resources is relevant to this theme because Okvau already supports meaningful production and earnings grew 196.3% in the past year, with forecasts indicating strong revenue expansion. High margins and a 28.3% ROE indicate the quality of current growth. Future outcomes depend on how pressure around funding and project execution is managed.

That execution puzzle is exactly what makes the analyst forecasts for Emerald Resources so useful, as it shows where expectations may be racing ahead of reality.

Mesoblast (ASX:MSB)

Mesoblast is a Melbourne based biotech focused on mesenchymal lineage cell therapies, with its High Growth High Conviction link coming from late stage candidates like Ryoncil and Remestemcel L. The business generated US$120 million from its allogeneic cellular medicines platform and carries a market value around A$2.6b.

Mesoblast taps directly into the High Growth High Conviction theme because its late stage cell therapy programs aim at large, difficult conditions where successful products can scale quickly. However, outcomes still rest on clinical data, regulation and execution.

"The first and only FDA approved mesenchymal stromal cell product in the U.S., Ryoncil, together with over 1,100 patents and established commercial scale manufacturing, positions Mesoblast to benefit if cell therapies gain wider medical adoption."

What happens to that growth story depends heavily on how one unresolved pressure shapes pricing power and the eventual path to margins.

That pressure point is exactly what the full narrative for Mesoblast unpacks, revealing how trial outcomes, capital needs and potential pricing power could be accelerating or stalling Mesoblast’s story.

Pinnacle Investment Management Group (ASX:PNI)

Pinnacle Investment Management Group runs a multi affiliate funds platform that helps high conviction boutique managers scale, earning A$109.7 million from funds management operations in Australia and carrying an equity value around A$3.3b.

Pinnacle Investment Management Group gives you exposure to a business that grows by helping other high conviction managers grow, using its distribution network, fund infrastructure and trustee services as the engine for that scaling.

"While 81% of affiliate strategies with a 5 year track record have outperformed, style shifts and performance fee cyclicality highlight that a larger A$61.3b pool of performance fee eligible FUM may not consistently translate into higher net margins or earnings in less favourable style periods."

What happens to future profitability hinges on how one less visible pressure shapes the balance between growth ambitions and the cost of supporting them.

That trade off is exactly what the full narrative for Pinnacle Investment Management Group unpacks, showing where fee potential, cost creep and manager performance risk might be masking Pinnacle’s next growth leg.

Seeking Alternatives Before The Crowd?

Fresh momentum does not wait. Breakout themes get spotted, capital flies in and the easy entry points are gone. Scan curated ideas while it still matters and act now.

• Spot income engines that aim to keep paying even when markets are choppy by reviewing a curated batch of 4 dividend fortresses.
• Ride the build out of next generation AI plumbing by scanning a hand picked group of 55 AI infrastructure stocks powering chips, data centers and critical hardware.
• Track companies wiring the energy transition by combing through a focused set of 41 power grid technology and infrastructure stocks before the theme shows up on every front page.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com